Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus

Nakai,Yasushi; Miyake,Makito; Morizawa,Yosuke; Hori,Shunta; Tatsumi,Yoshihiro; Anai,Satoshi; Onishi,Sayuri; Tanaka,Nobumichi; Fujimoto,Kiyohide

doi:10.3892/or.2016.5232

Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus

Authors:
- Yasushi Nakai
- Makito Miyake
- Yosuke Morizawa
- Shunta Hori
- Yoshihiro Tatsumi
- Satoshi Anai
- Sayuri Onishi
- Nobumichi Tanaka
- Kiyohide Fujimoto
View Affiliations

Affiliations: Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan
Published online on: November 8, 2016 https://doi.org/10.3892/or.2016.5232
Pages: 227-234

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We examined extracellular signal‑regulated kinase (ERK), 4E‑binding protein 1 (4EBP1) and p70 ribosomal S6 kinase (p70) as potential biomarkers for pretreatment prediction of the prognosis of patients with metastatic renal cell carcinoma (RCC) treated with sorafenib, sunitinib or everolimus. 786‑O and 769‑P cells were treated with sorafenib, sunitinib and everolimus. The expression of phosphorylated/total ERK, phosphorylated/total 4EBP1 and phosphorylated/total p70 was evaluated using western blotting. ERK, 4EBP1 and p70 were knocked down by siRNA in 786‑O and 769‑P cells. Then, the viability after treatment with each drug was assessed. Expression of phosphorylated (phospho)‑ERK, -4EBP1 and -p70 was immunohistochemically evaluated in radical nephrectomy specimens and correlated with progression‑free survival during treatment with each molecular targeting agent. Sorafenib inhibited the expression of phospho-ERK and -4EBP1 in 769‑P cells; sunitinib, phospho-ERK and -4EBP1 in 786‑O and 769‑P cells; and everolimus, phospho-p70 in 786‑O and 769‑P cells. Knockdown of ERK reduced sensitivity to sorafenib in both cell lines, knockdown of ERK and 4EBP1 reduced sensitivity to sunitinib in 769‑P cells, and knockdown of 4EBP1 and p70 reduced sensitivity to everolimus in 786‑O cells. High expression of phospho-ERK, -4EBP1 and -p70 correlated with better progression‑free survival in patients treated with sorafenib, sunitinib and everolimus, respectively. Our results indicate that phospho-ERK, -4EBP1 and/or -ERK, and phospho-p70 can be used as biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus, respectively.

View Figures

View References

1	Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM and Santoro M: BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 98:326–334. 2006. View Article : Google Scholar : PubMed/NCBI
2	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
3	Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al: TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
4	Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar : PubMed/NCBI
5	Rini BI and Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 23:1028–1043. 2005. View Article : Google Scholar : PubMed/NCBI
6	Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
7	Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al: RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
8	Szmit S, Langiewicz P, Złnierek J, Nurzyński P, Zaborowska M, Filipiak KJ, Opolski G and Szczylik C: Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res. 35:18–25. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kust D, Prpić M, Murgić J, Jazvić M, Jakšić B, Krilić D, Bolanča A and Kusić Z: Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy. Anticancer Res. 34:3177–3184. 2014.PubMed/NCBI
10	Di Fiore F, Rigal O, Ménager C, Michel P and Pfister C: Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer. 105:1811–1813. 2011. View Article : Google Scholar : PubMed/NCBI
11	Funakoshi T, Lee CH and Hsieh JJ: A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev. 40:533–547. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sheppard K, Kinross KM, Solomon B, Pearson RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
13	Miyake M, Ishii M, Kawashima K, Kodama T, Sugano K, Fujimoto K and Hirao Y: siRNA-mediated knockdown of the heme synthesis and degradation pathways: Modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines. Photochem Photobiol. 85:1020–1027. 2009. View Article : Google Scholar : PubMed/NCBI
14	Miyake M, Fujimoto K, Anai S, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, et al: Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol Rep. 25:653–660. 2011. View Article : Google Scholar : PubMed/NCBI
15	Zhou X, Tan M, Hawthorne V Stone, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 10:6779–6788. 2004. View Article : Google Scholar : PubMed/NCBI
16	Garcia-Roig M, Ortiz N and Lokeshwar V: Molecular marker for predicting treatment response in advanced renal cell carcinoma: Does the promise fulfill clinical need? Curr Urol Rep. 15:3752014. View Article : Google Scholar : PubMed/NCBI
17	Zhang Z, Zhou X, Shen H, Wang D and Wang Y: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Med. 7:412009. View Article : Google Scholar : PubMed/NCBI
18	Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
19	Campbell L, Nuttall R, Griffiths D and Gumbleton M: Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer. 115:3457–3467. 2009. View Article : Google Scholar : PubMed/NCBI
20	Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M and Yoshida O: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55:4182–4187. 1995.PubMed/NCBI
21	You D, Song SH, Cho YM, Lee JL, Jeong IG, Song C, Hong JH, Kim CS and Ahn H: Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. World J Urol. 33:111–118. 2015. View Article : Google Scholar : PubMed/NCBI
22	Terakawa T, Miyake H, Kusuda Y and Fujisawa M: Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol. 31:493–498. 2013. View Article : Google Scholar : PubMed/NCBI
23	Trinh XB, Tjalma WAA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY and van Dam PA: The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 100:971–978. 2009. View Article : Google Scholar : PubMed/NCBI
24	Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M and Naito S: Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol. 40:1691–1696. 2012.PubMed/NCBI
25	Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F and Hershman JM: Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid. 20:965–974. 2010. View Article : Google Scholar : PubMed/NCBI
26	Robb VA, Karbowniczek M, Klein-Szanto AJ and Henske EP: Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol. 177:346–352. 2007. View Article : Google Scholar : PubMed/NCBI
27	Nishikawa M, Miyake H, Harada K and Fujisawa M: Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med Oncol. 31:7922014. View Article : Google Scholar : PubMed/NCBI
28	Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, et al: Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 46:225–233. 2014. View Article : Google Scholar : PubMed/NCBI
29	Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, et al: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 5:379–385. 2007. View Article : Google Scholar : PubMed/NCBI